Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Finished Goods (2019 - 2025)

Aytu Biopharma (AYTU) has disclosed Finished Goods for 7 consecutive years, with $5.6 million as the latest value for Q4 2025.

  • Quarterly Finished Goods fell 24.81% to $5.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $5.6 million through Dec 2025, down 24.81% year-over-year, with the annual reading at $8.9 million for FY2025, 45.33% up from the prior year.
  • Finished Goods for Q4 2025 was $5.6 million at Aytu Biopharma, down from $7.9 million in the prior quarter.
  • The five-year high for Finished Goods was $12.0 million in Q4 2021, with the low at $5.6 million in Q4 2025.
  • Average Finished Goods over 5 years is $8.3 million, with a median of $8.4 million recorded in 2022.
  • The sharpest move saw Finished Goods surged 99.93% in 2021, then plummeted 32.89% in 2022.
  • Over 5 years, Finished Goods stood at $12.0 million in 2021, then tumbled by 30.08% to $8.4 million in 2022, then increased by 3.73% to $8.7 million in 2023, then fell by 13.66% to $7.5 million in 2024, then dropped by 24.81% to $5.6 million in 2025.
  • According to Business Quant data, Finished Goods over the past three periods came in at $5.6 million, $7.9 million, and $8.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.